178 related articles for article (PubMed ID: 26073354)
21. Investigation of bioequivalence of a new fixed-dose combination of acarbose and metformin with the corresponding loose combination as well as the drug-drug interaction potential between both drugs in healthy adult male subjects.
Kim S; Jang IJ; Shin D; Shin DS; Yoon S; Lim KS; Yu KS; Li J; Zhang H; Liu Y; Brendel E; Blode H; Wang Y
J Clin Pharm Ther; 2014 Aug; 39(4):424-31. PubMed ID: 24806030
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.
Horie Y; Kanada S; Watada H; Sarashina A; Taniguchi A; Hayashi N; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2011 Jul; 33(7):973-89. PubMed ID: 21723606
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers.
Kim BH; Shin KH; Kim J; Lim KS; Kim KP; Kim JR; Cho JY; Shin SG; Jang IJ; Yu KS
Clin Ther; 2009 Nov; 31(11):2755-64. PubMed ID: 20110017
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers.
Graefe-Mody EU; Jungnik A; Ring A; Woerle HJ; Dugi KA
Int J Clin Pharmacol Ther; 2010 Oct; 48(10):652-61. PubMed ID: 20875371
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the bioavailability and tolerability of fixed-dose combination glimepiride/metformin 2/500-mg tablets versus separate tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy Korean volunteers.
Gu N; Kim BH; Rhim H; Chung JY; Kim JR; Shin HS; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
Clin Ther; 2010 Jul; 32(7):1408-18. PubMed ID: 20678687
[TBL] [Abstract][Full Text] [Related]
26. Bioequivalence of fixed-dose combinations of dapagliflozin and metformin with single-component tablets in healthy subjects and the effect of food on bioavailability.
de Bruin TW; Reele S; Hamer-Maansson JE; Parikh S; Tang W
Clin Pharmacol Drug Dev; 2016 Mar; 5(2):118-30. PubMed ID: 27138025
[TBL] [Abstract][Full Text] [Related]
27. A validated LC-MS/MS method for simultaneous determination of linagliptin and metformin in spiked human plasma coupled with solid phase extraction: Application to a pharmacokinetic study in healthy volunteers.
Abbas Moussa B; Mahrouse MA; Fawzy MG
J Pharm Biomed Anal; 2019 Jan; 163():153-161. PubMed ID: 30312887
[TBL] [Abstract][Full Text] [Related]
28. Linagliptin: a review of its use in the management of type 2 diabetes mellitus.
Deeks ED
Drugs; 2012 Sep; 72(13):1793-824. PubMed ID: 22913735
[TBL] [Abstract][Full Text] [Related]
29. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes.
Forst T; Uhlig-Laske B; Ring A; Graefe-Mody U; Friedrich C; Herbach K; Woerle HJ; Dugi KA
Diabet Med; 2010 Dec; 27(12):1409-19. PubMed ID: 21059094
[TBL] [Abstract][Full Text] [Related]
30. Bioequivalence and Pharmacokinetic Evaluation of Two Metformin Hydrochloride Tablets Under Fasting and Fed Conditions in Healthy Chinese Volunteers.
Huang XM; Wang GZ; He BB; Gao T; Long P; Zhang BK
Clin Pharmacol Drug Dev; 2020 Nov; 9(8):910-917. PubMed ID: 32936533
[TBL] [Abstract][Full Text] [Related]
31. Relative bioavailability and bioequivalence of metforphin hydrochloride extended-released and immediate-released tablets in healthy Chinese volunteers.
Li J; Jin Y; Wang TY; Lü XW; Li YH
Eur J Drug Metab Pharmacokinet; 2007; 32(1):21-8. PubMed ID: 17479540
[TBL] [Abstract][Full Text] [Related]
32. Effect of linagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.
Graefe-Mody EU; Brand T; Ring A; Withopf B; Stangier J; Iovino M; Woerle HJ
Int J Clin Pharmacol Ther; 2011 May; 49(5):300-10. PubMed ID: 21543033
[TBL] [Abstract][Full Text] [Related]
33. Effect of multiple oral doses of linagliptin on the steady-state pharmacokinetics of a combination oral contraceptive in healthy female adults: an open-label, two-period, fixed-sequence, multiple-dose study.
Friedrich C; Port A; Ring A; Graefe-Mody U; Giessmann T; Iovino M; Woerle HJ
Clin Drug Investig; 2011; 31(9):643-53. PubMed ID: 21714581
[TBL] [Abstract][Full Text] [Related]
34. Assessment of the pharmacokinetic interaction between the novel DPP-4 inhibitor linagliptin and a sulfonylurea, glyburide, in healthy subjects.
Graefe-Mody U; Rose P; Ring A; Zander K; Iovino M; Woerle HJ
Drug Metab Pharmacokinet; 2011; 26(2):123-9. PubMed ID: 21084763
[TBL] [Abstract][Full Text] [Related]
35. Fed and Fasted Single-dose Assessment of Bioequivalence of Dapagliflozin and Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects.
Boulton DW; Chang M; Griffen SC; Kitaura C; Lubin S; Pollack A; LaCreta F
Clin Ther; 2016 Jan; 38(1):99-109. PubMed ID: 26682500
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of single and multiple oral doses of 5 mg linagliptin in healthy Chinese volunteers.
Friedrich C; Shi X; Zeng P; Ring A; Woerle HJ; Patel S
Int J Clin Pharmacol Ther; 2012 Dec; 50(12):889-95. PubMed ID: 23073142
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus.
Friedrich C; Glund S; Lionetti D; Kissling CJ; Righetti J; Patel S; Graefe-Mody U; Retlich S; Woerle HJ
Br J Clin Pharmacol; 2013 Sep; 76(3):445-54. PubMed ID: 23331248
[TBL] [Abstract][Full Text] [Related]
38. Safety and pharmacokinetic interaction between fotagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin in healthy subjects.
Ding Y; Zhang H; Li C; Zheng W; Wang M; Li Y; Sun H; Wu M
Expert Opin Drug Metab Toxicol; 2021 Jun; 17(6):725-731. PubMed ID: 33899649
[TBL] [Abstract][Full Text] [Related]
39. Oral antidiabetic drugs: bioavailability assessment of fixed-dose combination tablets of pioglitazone and metformin. Effect of body weight, gender, and race on systemic exposures of each drug.
Karim A; Slater M; Bradford D; Schwartz L; Zhao Z; Cao C; Laurent A
J Clin Pharmacol; 2007 Jan; 47(1):37-47. PubMed ID: 17192500
[TBL] [Abstract][Full Text] [Related]
40. Pharmacodynamic effects of voglibose administered alone, administered with metformin, and administered with metformin in a fixed-dose combination in healthy Korean subjects
.
Kim HS; Oh M; Kim EJ; Song GS; Kim EY; Shin JG
Int J Clin Pharmacol Ther; 2018 Nov; 56(11):544-550. PubMed ID: 30178742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
